LDL cholesterol often trends downward
Semaglutide may cause acute kidney injury or worsen chronic kidney disease, potentially requiring dialysis
Avoid excessive alcohol consumption to reduce the risk of pancreatitis or hypoglycemia
Check the pen: confirm the medication is clear and colorless and the pen is the correct dose
Some people choose to microdose Wegovy in an attempt to reduce these side effects, as symptoms are typically milder at lower doses
Methodology and Sources This analysis is based on publicly available sources as of December 26, 2025: FDA communications: Compounding safety alerts, prescribing information, and regulatory guidance Novo Nordisk announcements: Wegovy pill approval, OASIS 4 trial results, pricing disclosures Independent reporting and primary sources: ABC News coverage and Novo Nordisks announcement on December 22, 2025 FDA oral Wegovy approval MEDVi terms and disclosures: Platform structure, pricing, and regulatory disclaimers Key Sources Cited: ABC News: "FDA approves Wegovy pill for weight loss" (December 22, 2025) Novo Nordisk: Official press release on FDA approval and OASIS 4 trial data (December 22, 2025) FDA Safety Communications: 20242025 alerts on compounded semaglutide dosing errors All regulatory references are based on FDA publications and third-party reporting available at the time of publication
